Hematology AdvisorCombination Ponatinib Plus Blinatumomab Shows High Efficacy in Ph-Positive ALL

Read the original article

A chemotherapy-free combination of ponatinib and blinatumomab shows promising efficacy in treating Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to a study published in the Journal of Clinical Oncology. The phase 2 trial results demonstrate high response rates and favorable survival outcomes, potentially offering a new treatment approach for this patient population.

Key Points:

• The study evaluated 60 patients with Ph-positive ALL who received frontline blinatumomab plus ponatinib.
• Complete response rate was 95%, with a complete molecular response rate of 83%.
• 98% of patients achieved minimal residual disease negativity.
• 3-year event-free survival rate was 77% (95% CI, 60-87).
• 3-year overall survival rate was 91% (95% CI, 76-97).
• 21 patients discontinued therapy, with 7 due to toxicity and 6 due to relapse.
• Only one patient proceeded to stem cell transplantation.

“In summary, the simultaneous ponatinib-blinatumomab regimen continues to demonstrate robust efficacy and safety in Ph-positive ALL.”

More on Leukemia